ABUSE RESISTANT TRANSDERMAL BUPRENORPHINE FOR OPIATE

阿片拮抗剂治疗是近期戒断的重要治疗方法。 吸毒成瘾者丁丙诺啡是一种混合激动剂-拮抗剂的药物 防止吗啡类药物引起的任何高血压的特性， 消除生理强化。BIOTEK建议改善 拮抗剂治疗，通过开发经皮递送系统， 丁丙诺啡，一种非常有效的药物，受试者首选 美沙酮或纳洛酮。透皮丁丙诺啡可以避免 频繁的临床访问的不便，以及稳定的维护， 丁丙诺啡的次级激动剂作用应提供更积极的 加强和改善遵守。因为丁丙诺啡很容易 为了防止滥用，BIOTEK建议通过以下方式保护补丁免受破坏： 加入一种经皮无活性形式的纳洛酮， 丁丙诺啡的轻度欣快和沉淀物从其他 如果静脉注射的话。BIOTEK此前已经证明了高 丁丙诺啡的透皮递送速率。在第一阶段，我们将尝试 为了从制剂中获得类似的丁丙诺啡速率， 含有经皮无活性纳洛酮，目的是开发一种 抗滥用的48小时丁丙诺啡贴剂

Opiate antagonist therapy is an important treatment for recently withdrawn narcotic addicts. Buprenorphine is a drug with mixed agonist-antagonist properties which prevents any high from morphine-like drugs, thereby eliminating physiological reinforcement. BIOTEK proposes to improve antagonist therapy by developing a transdermal delivery system for buprenorphine, a very effective drug preferred by subjects to either methadone or naltrexone. Transdermal buprenorphine would avoid the inconvenience of frequent clinical visits, and steady maintenance of the secondary agonist action of buprenorphine should provide more positive reinforcement and improve compliance. Because buprenorphine is susceptible to abuse, BIOTEK proposes to protect the patches against subversion by adding a transdermally inactive form of naloxone, a drug which counteracts the mild euphoria of buprenorphine and precipitates withdrawal from other opiates if taken intravenously. BIOTEK has previously demonstrated high transdermal delivery rates for buprenorphine. In Phase I we will attempt to achieve similar rates for buprenorphine from a formulation which contains transdermally inactive naloxone, with the goal of developing an abuse-resistant 48 hour buprenorphine patch.